Myriad Genetics Inc (MYGN)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $542.92M
Last updated: Nov 17, 2026 at 11:06 AM ET
Myriad Genetics Inc (MYGN) Financials: Revenue, Profit and Cash Flow
Myriad Genetics reported revenue of $824.50M for the fiscal year ended Dec 31, 2025, down 1.6% from the year before. That year, net income was -$365.90M with a net margin of -44.4%, operating cash flow was $1.80M and free cash flow was -$13.80M. The quarter ended Sep 30, 2026 had revenue of $202.70M and net income of -$43.90M.
Revenue and Margins
The operating margin was -47.0% in the fiscal year ended Dec 2025. Over the 7 years to Dec 2025, revenue grew from $772.60M, a compound annual rate of 0.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $824.50M | -1.6% | 69.9% | -47.0% | -44.4% |
| Dec 2024 | $837.60M | +11.2% | 69.9% | -14.7% | -15.2% |
| Dec 2023 | $753.20M | +11.0% | 68.6% | -34.2% | -35.0% |
| Dec 2022 | $678.40M | -1.8% | 70.2% | -20.7% | -16.5% |
| Dec 2021 | $690.60M | +24.0% | 71.4% | -27.6% | -3.9% |
| Dec 2020 | $557.00M | N/A | 68.0% | -35.0% | -40.2% |
| Jun 2020 | $638.60M | N/A | 70.9% | -36.3% | -31.3% |
| Dec 2019 | $851.10M | N/A | 76.4% | 0.9% | 0.5% |
| Jun 2019 | $851.10M | N/A | 76.4% | 0.9% | 0.5% |
| Dec 2018 | $772.60M | N/A | 77.1% | 15.4% | 17.0% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Jun 2020 | Dec 2019 | Jun 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $824.50M | $837.60M | $753.20M | $678.40M | $690.60M | $557.00M | $638.60M | $851.10M | $851.10M | $772.60M |
| Cost of revenue | $247.90M | $252.20M | $236.20M | $202.00M | $197.60M | $178.20M | $186.10M | $201.00M | $201.00M | $177.20M |
| Gross profit | $576.60M | $585.40M | $517.00M | $476.40M | $493.00M | $378.80M | $452.50M | $650.10M | $650.10M | $595.40M |
| Research and development | $106.80M | $113.40M | $88.70M | $85.40M | $81.90M | $80.90M | $77.20M | $85.90M | $85.90M | $70.80M |
| Operating income | -$387.20M | -$123.50M | -$257.40M | -$140.60M | -$190.50M | -$194.80M | -$231.70M | $7.60M | $7.60M | $118.70M |
| Net income | -$365.90M | -$127.30M | -$263.30M | -$112.00M | -$27.20M | -$223.70M | -$199.60M | $4.60M | $4.40M | $131.00M |
| EBITDA | -$332.70M | -$61.20M | -$199.90M | -$87.30M | $11.60M | -$123.40M | -$143.50M | $85.00M | $81.80M | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $202.70M | $190.70M | $200.40M | $209.80M | $205.70M | $213.10M | $195.90M | $210.60M | $213.30M | $211.50M | $202.20M | $196.60M |
| Gross profit | $137.70M | $127.00M | $137.60M | $146.80M | $143.80M | $151.80M | $134.20M | $150.90M | $149.80M | $147.10M | $137.60M | $135.00M |
| Operating income | -$39.90M | -$38.90M | -$30.70M | -$5.70M | -$23.30M | -$329.20M | -$29.00M | -$39.10M | -$20.00M | -$36.50M | -$27.90M | -$31.40M |
| Net income | -$43.90M | -$43.20M | -$34.10M | -$7.90M | -$27.40M | -$330.50M | -$100.00K | -$42.50M | -$22.10M | -$36.70M | -$26.00M | -$31.20M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $126.80M by $22.80M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Jun 2020 | Dec 2019 | Jun 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $706.60M | $1.03B | $1.15B | $1.20B | $1.32B | $1.42B | $1.42B | $1.56B | $1.56B | $1.17B |
| Current assets | $332.60M | $298.00M | $313.60M | $274.60M | $484.80M | $389.40M | $389.40M | $348.60M | $348.60M | $326.40M |
| Cash and equivalents | $149.60M | $102.40M | $132.10M | $56.90M | $257.40M | $117.00M | $117.00M | $93.20M | $93.20M | $110.90M |
| Total liabilities | $338.60M | $326.50M | $363.30M | $312.90M | $352.90M | $537.80M | $537.80M | $473.80M | $473.80M | $209.20M |
| Short-term debt | $6.90M | $12.80M | $16.20M | $14.10M | $13.00M | $13.60M | N/A | $78.90M | N/A | $68.30M |
| Long-term debt | $119.90M | $39.60M | $38.50M | $0 | N/A | $224.80M | $224.80M | $224.40M | $233.50M | N/A |
| Shareholder equity | $368.00M | $701.10M | $783.20M | $885.80M | $967.80M | $881.00M | $881.00M | $1.09B | $1.09B | $964.90M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $609.20M | $638.90M | $673.70M | $706.60M | $728.10M | $677.30M | $1.01B | $1.03B | $1.08B | $1.09B | $1.11B | $1.15B |
| Total liabilities | $340.20M | $335.00M | $336.30M | $338.60M | $355.30M | $289.20M | $301.20M | $326.50M | $349.60M | $344.60M | $350.50M | $363.30M |
| Cash and equivalents | $107.10M | $115.20M | $124.40M | $149.60M | $145.40M | $74.40M | $91.80M | $102.40M | $99.90M | $92.40M | $96.90M | $132.10M |
| Shareholder equity | $269.00M | $303.90M | $337.40M | $368.00M | $372.80M | $388.10M | $704.90M | $701.10M | $731.70M | $740.50M | $760.00M | $783.20M |
Cash Flow
In the fiscal year ended Dec 2025, capital expenditures exceeded operating cash flow, leaving negative free cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Jun 2020 | Dec 2019 | Jun 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.80M | -$8.70M | -$110.90M | -$106.30M | $18.60M | $83.70M | $60.70M | $83.70M | $83.70M | $115.90M |
| Capital expenditures | $15.60M | $19.00M | $63.20M | $45.30M | $18.00M | $8.60M | $10.20M | $8.60M | $8.60M | $8.40M |
| Free cash flow | -$13.80M | -$27.70M | -$174.10M | -$151.60M | $600.00K | $75.10M | $50.50M | $75.10M | $75.10M | $107.50M |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | $340.00M | N/A | $340.00M | N/A | N/A |
| Share repurchases | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $50.00M | N/A |
| Investing cash flow | -$27.40M | -$11.90M | $31.90M | -$77.50M | $274.40M | $19.30M | $19.30M | -$286.40M | -$286.40M | -$11.60M |
| Financing cash flow | $64.20M | -$7.40M | $152.90M | -$8.00M | -$150.60M | $182.30M | -$10.00M | $182.30M | $182.30M | -$95.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.50M | -$8.30M | -$15.70M | $10.60M | $21.10M | -$13.60M | -$16.30M | $6.60M | $700.00K | $2.60M | -$18.60M | -$54.70M |
| Capital expenditures | $1.80M | $2.10M | $5.40M | $4.70M | $2.80M | $2.80M | $5.30M | $3.60M | $3.50M | $5.20M | $6.70M | $3.40M |
| Free cash flow | -$8.30M | -$10.40M | -$21.10M | $5.90M | $18.30M | -$16.40M | -$21.60M | $3.00M | -$2.80M | -$2.60M | -$25.30M | -$58.10M |
Frequently Asked Questions About MYGN
What is Myriad Genetics' annual revenue?
Myriad Genetics reported revenue of $824.50M for the fiscal year ended Dec 31, 2025.
How fast is Myriad Genetics' revenue growing?
Revenue was down 1.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 6.7%.
Is Myriad Genetics profitable?
No. Myriad Genetics reported net income of -$365.90M for the fiscal year ended Dec 31, 2025, with a net margin of -44.4%.
How much free cash flow does MYGN generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $1.80M minus capital expenditures of $15.60M produced free cash flow of -$13.80M.
How much debt does Myriad Genetics have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $119.90M, short-term debt of $6.90M and cash and equivalents of $149.60M.
MYGN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts